Lucid Diagnostics (LUCD) Plunges 33.94% to 2025 Low on Equity Raise

Lucid Diagnostics (LUCD) experienced a significant decline, with its share price falling to its lowest level since February 2025 today, marking an intraday drop of 33.94%.

Lucid Diagnostics' recent equity raise activities have been cited as the primary cause of its stock price decline. The company announced a public offering of 12.5 million shares at $1.20 per share, resulting in substantial shareholder dilution and a more than 21% drop in share price during after-hours trading. This move has raised concerns about the company's financial and operational risks, as evidenced by its negative P/E ratio and lack of dividends, which have contributed to the stock's negative momentum.